The estimated Net Worth of Masoud Toloue is at least $4.37 Millón dollars as of 13 August 2024. Mr Toloue owns over 19,000 units of Quanterix Corp stock worth over $4,274,216 and over the last 3 years he sold QTRX stock worth over $99,083.
Mr has made over 5 trades of the Quanterix Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 19,000 units of QTRX stock worth $207,100 on 13 August 2024.
The largest trade he's ever made was buying 105,000 units of Quanterix Corp stock on 12 August 2022 worth over $1,095,150. On average, Mr trades about 3,727 units every 23 days since 2021. As of 13 August 2024 he still owns at least 354,119 units of Quanterix Corp stock.
You can see the complete history of Mr Toloue stock trades at the bottom of the page.
Masoud Toloue is the Pres & Head of Diagnostics Bus. at Quanterix Corp.
Mr Toloue is 41, he's been the Pres & Head of Diagnostics Bus. of Quanterix Corp since . There are 20 older and 1 younger executives at Quanterix Corp. The oldest executive at Quanterix Corp is Dr. David R. Walt Ph.D., 68, who is the Co-Founder, Chairman of Scientific Advisory Board & Independent Director.
Masoud's mailing address filed with the SEC is C/O QUANTERIX CORPORATION, 900 MIDDLESEX TURNPIKE, BILLERICA, MA, 01821.
Over the last 7 years, insiders at Quanterix Corp have traded over $25,118,881 worth of Quanterix Corp stock and bought 1,481,095 units worth $18,701,541 . The most active insiders traders include David R Walt, Paul M Meister y Keith Crandell. On average, Quanterix Corp executives and independent directors trade stock every 7 days with the average trade being worth of $100,483. The most recent stock trade was executed by Masoud Toloue on 13 August 2024, trading 19,000 units of QTRX stock currently worth $207,100.
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
Quanterix Corp executives and other stock owners filed with the SEC include: